{
    "organizations": [],
    "uuid": "c6334eacd64a33a1c9da9b8eddc6c9bcf4edec7c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-actinium-pharmaceuticals-announces/brief-actinium-pharmaceuticals-announces-trial-to-study-actimab-a-in-combination-with-clag-m-idUSFWN1PW0PO",
    "ord_in_thread": 0,
    "title": "BRIEF-Actinium Pharmaceuticals Announces Trial To Study Actimab-A In Combination With CLAG-M",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Actinium Pharmaceuticals Inc:\n* ACTINIUM PHARMACEUTICALS ANNOUNCES TRIAL TO STUDY ACTIMAB-A IN COMBINATION WITH CLAG-M FOR RELAPSED OR REFRACTORY AML PATIENTS\n* ACTINIUM PHARMA - COMBINATION ALIGNS WITH ACTINIUMâ€˜S FOCUS ON IMPROVING BONE MARROW TRANSPLANT ACCESS AND OUTCOMES THROUGH IMPROVED MYELOABLATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T20:38:00.000+02:00",
    "crawled": "2018-02-07T22:23:34.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "actinium",
        "pharmaceutical",
        "inc",
        "actinium",
        "pharmaceutical",
        "announces",
        "trial",
        "study",
        "combination",
        "relapsed",
        "refractory",
        "aml",
        "patient",
        "actinium",
        "pharma",
        "combination",
        "aligns",
        "actinium",
        "focus",
        "improving",
        "bone",
        "marrow",
        "transplant",
        "access",
        "outcome",
        "improved",
        "myeloablation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}